STL Index for: PDE-4

Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis

Crisaborole provides a novel and safe treatment option for mild-to-moderate AD.

Use of Topical Crisaborole for Treating Dermatitis in a Variety of Dermatology Settings

The discussed cases reflect the panels’ real-world clinical experience with crisaborole for the treatment of patients with AD and the off-label treatment of irritant dermatitis.

Diagnosis and Management of Atopic Dermatitis for Family Physicians: A Clinical Review

Atopic dermatitis (AD) is a chronic and pruritic inflammatory disease that affects a wide age range of patients causing significant impact on their quality of life. There has been a recently updated consensus paper on the treatment of mild-to-moderate AD published by an expert panel of dermatologists and pediatricians. Family physicians are well equipped to manage...

Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis

Crisaborole represents a novel and efficacious therapeutic approach for the treatment of mild to moderate Atopic Dermatitis and demonstrates early and continued decrease in pruritus, which improves quality of life and reduces the potential risk of infection and scarring.

Atopic Dermatitis: Pediatric Use of Crisaborole

An overview to AD care and focus our review to topical agents used in AD including topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI) and discuss the newest topical agent accessible in the physician's armamentarium, crisaborole.

Apremilast in the Treatment of Psoriasis and Psoriatic Arthritis (Family Practice)

Phosphodiesterase 4 (PDE4) is a key enzyme in the regulation of immune responses of inflammatory diseases through degradation of the second messenger, cyclic adenosine 3',5'-monophosphate (cAMP). Apremilast (APR), a selective PDE4 inhibitor, has been shown to reduce the production of pro-inflammatory cytokines.

Apremilast in the Treatment of Psoriasis and Psoriatic Arthritis

Apremilast, a selective PDE4 inhibitor, has been shown to reduce the production of pro-inflammatory cytokines. A review of clinical trial data treating psoriasis, considering adverse effects, efficacy and tolerance.

Update on Drugs and Drug News: January-February 2015

Update on Apremilast tablets (Otezla®), Collagenase clostridium histolyticum for injection (Xiaflex®), Afamelanotide 16 mg subcutaneous bioresorbable implants (Scenesse®), Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Dupilumab SC injection, Apremilast tablets (Otezla®).

Small Molecules: An Overview of Emerging Therapeutic Options in the Treatment of Psoriasis

While biologics changed the way psoriasis is treated by providing effective targeted therapy, they are not without limitations. Small molecules are emerging therapeutic options for the treatment of psoriasis.

POPULAR